Sales & Reports ›

Novartis has delivered dynamic sales and earnings over the past 10 years. The following information provides more information on the strong financial performance of the company.

Full-year results

Quarterly Reports

Financial Spreadsheets

Annual Reports

20F Reports

SEC Filings

US Investor Relations Contacts ›

If you would like investor information, please visit our Novartis US Corporate website for a full list of investor relations contacts.

Share Data and Analysis ›

Learn more about the history and performance of Novartis shares on the NYSE and SWX, ownership details and dividend history.

Investors

Latest News ›

6-Jan-2009
FDA approves once-yearly Reclast® for osteoporosis in men

12-Dec-2008
First Phase III results for FTY720, a novel oral therapy for MS, show superior efficacy compared to interferon beta-1a

13-Nov-2008
US FDA approves 30-minute onset of action for Focalin® XR, bringing potential benefits to ADHD patients during early morning period

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis' website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.